Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallopamil
- Development stage
- Phase 2
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Inhalation
01
Overview
Gallopamil is a small molecule L-type calcium channel blocker, structurally related to verapamil. It acts as an antiarrhythmic and antihypertensive agent, primarily used in the management of angina pectoris, certain arrhythmias (abnormal heart rhythms), and has been investigated for use in asthma. Gallopamil works by inhibiting the influx of calcium ions through L-type calcium channels in cardiac and smooth muscle cells, leading to decreased myocardial contractility, reduced heart rate, vasodilation, and lowered blood pressure. This mechanism helps reduce coronary vascular resistance and increases coronary blood flow[2][3][4][5]. Clinical studies have also explored its potential benefit in reducing airway remodeling in severe asthma[7].
- Brand names
- Procorum
- Other names
- gallopamil hydrochloridegalopamilogallopamillum
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D)
Beyond the preview
Go deeper on gallopamil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallopamil.